The pharmacological basis for the treatment of perennial allergic rhinitis and non‐allergic rhinitis with topical corticosteroids
Author:
Abstract
The currently available respiratory topical corticosteroids are all effective at reducing the nasal symptoms of itch, sneezing, rhinorrhoea and obstruction associated with allergic rhinitis. The mechanism of action of corticosteroids is related to their anti‐innammatory activities. They have been documented to prevent fluid exudation and reduce the number of circulating inflammatory cells, including lymphocytes, mast cells, basophils, eosinophils, macrophages, and neutrophils. This occurs through multiple mechanisms, e.g. eosinophil infiltration is suppressed by preventing cytokine production, reducing local mechanisms of tissue infiltration, and decreasing eosinophil survival. Furthermore, corticosteroids also reduce preformed and newly‐generated mediators (e.g. histamine, tryptase, prostanoids, leukotrienes), and inhibit production of cytokines and chemokines by inflammatory cells (e.g. IL‐1 through IL‐6, IL‐8, RANTES, TNF‐α, IFN‐γ and GM‐CSF). The currently available corticosteroids differ pharmacologically. Fluticasone propionate appears to have the greatest affinity for the glucocorticoid receptor, and binds more quickly and dissociates more slowly from the receptor compared with other corticosteroids, suggesting a more prolonged duration of action. Its increased specificity for respiratory tissue may lead to greater potency with less potential for systemic adverse effects. Fluticasone propionate has been compared with other corticosteroids in animal models for relative topical and systemic potency, and according to these data. it has the most favourable risk‐benefit ratio.Keywords
This publication has 40 references indexed in Scilit:
- Effect of intranasal fluticasone proprionate on the immediate and late allergic reaction and nasal hyperreactivity in patients with a house dust mite allergyClinical & Experimental Allergy, 1995
- Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitisClinical Therapeutics, 1995
- Quantification of resident inflammatory cells in the human nasal mucosaJournal of Allergy and Clinical Immunology, 1993
- The effect of platelet-activating factor on the generation of superoxide anion in human eosinophils and neutrophilsJournal of Allergy and Clinical Immunology, 1991
- Effect of topical corticosteroids on seasonally induced increases in nasal mast cellsBMJ, 1988
- Inhibition of Mediator Release in Allergic Rhinitis by Pretreatment with Topical GlucocorticosteroidsNew England Journal of Medicine, 1987
- Direct in vivo evidence for mast cell degranulation during allergen-induced reactions in manJournal of Allergy and Clinical Immunology, 1986
- Inflammatory Mediators in Late Antigen-Induced RhinitisNew England Journal of Medicine, 1985
- Mediators of InflammationAnnual Review of Immunology, 1983
- Identification of several species of phospholipase inhibitory protein(s) by radioimmunoassay for lipomodulinBiochemical and Biophysical Research Communications, 1982